Chinese Journal of Pharmacovigilance ›› 2015, Vol. 12 ›› Issue (8): 506-507.
Previous Articles Next Articles
PAN Kun-ming, LIANG Yan, ZHOU Ying, et al
Received:2015-09-02
Revised:2015-09-02
Online:2015-08-08
Published:2015-09-02
CLC Number:
PAN Kun-ming, LIANG Yan, ZHOU Ying, et al. One Case of Pure Red Cell Aplastic Anemia Induced by Isoniazid Combined with Rifapentine[J]. Chinese Journal of Pharmacovigilance, 2015, 12(8): 506-507.
Add to citation manager EndNote|Ris|BibTeX
| [1] Fisch P, Handgretinger R, Schaefer H E. Pure Red Cell Aplasia[J]. British Journal of Haematology, 2000, 111(4):1010-1020. [2] Blumer J L, Reed M D. Clinical pharmacology of aminoglycoside antibiotics in pediatrics[J]. Pediatr Clin North Am, 1983, 30(1):195-208. [3] Aouam K, Chaabane A, Loussaief C, et al. Adverse effects of antitub-ercuLar drugs:epidemioLogy, mechanisms, and patient management[J]. Med MaL Infect, 2007,37(5): 253-261. [4] Hoffman R, McPhedran P, Benz E J, et al. Isoniazid-induced pure red ceLL apLasia[J]. Am J Med Sci,1983, 286(1): 2-9. [5] Campbell E A, Korzheva N, Mustaev A, et al. Structural mechanism for rifampicin inhibition of bacterial rna polymerase[J]. Cell,2001,104(6):901-912. [6] 陈陵,刘长征. 异烟肼引起纯红细胞再生障碍性贫血1例报告[J]. 实用儿科杂志, 1991, 6(4) :189. [7] Claiborne R A, Dutt A K. Isoniazid-induced pure red cell aplasia[J]. Am Rev Respir Dis, 1985 ,131(6):947-949. [8] 丁国林. 利福平引起再生障碍性贫血一例报告[J].吉林医药,1985,6(4): 57-58. [9] Mariette X, MitjaviLa M T, MouLinie J P, et al. Rifampicin-induced pure red cell aplasia [J]. Am J Med, 1989, 87(4):459-460. [10] Loulergue P, Mir O, Dhote R. Pure red blood cell aplasia and isoniazid use[J]. Emerg Infect Dis, 2007 , 13(9):1427-1428. [11] 黄丹青,张云志,王浩楠,等. 异烟肼致急性再生障碍性贫血1例[J].药物流行病学杂志, 2007, 16(2): 121-122. |
| [1] | LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850. |
| [2] | WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855. |
| [3] | XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862. |
| [4] | CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875. |
| [5] | CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882. |
| [6] | ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888. |
| [7] | SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895. |
| [8] | SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919. |
| [9] | YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923. |
| [10] | KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927. |
| [11] | LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932. |
| [12] | LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936. |
| [13] | ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940. |
| [14] | ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943. |
| [15] | CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
